Special Issue "Targetable Pathways in Advanced Bladder Cancer"
Deadline for manuscript submissions: 5 April 2022.
Bladder cancer impacts more than half a million persons annually across the world and represents the sixth most common cause of cancer in men globally. Bladder cancer progresses through multiple stages, beginning with non-invasive disease and advancing to high-grade and highly invasive or metastatic disease in some patients. Advanced bladder cancer embodies the later stages of this progression spectrum to include muscle-invasive bladder cancer and metastatic disease. Whereas patients with earlier stages of bladder cancer undergo treatment with cystoscopic resection and possibly Bacillus Calmette–Guérin (BCG) therapy, patients with advanced bladder cancer require radical cystectomy with lymph node dissection with or without neoadjuvant chemotherapy. Over the past decade, however, new therapeutic approaches have evolved that may offer expanded options for patients with advanced disease, including radiation therapy, immunotherapy, and new targeted therapy agents.
Dr. Donna Hansel
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- bladder cancer
- urothelial carcinoma
- growth factor
- tyrosine kinase receptor
- targeted therapy